Download PDF
TumorDiagnostik & Therapie 2012; 33(01): 42-49
DOI: 10.1055/s-0031-1299092
Thieme Onkologie aktuell
© Georg Thieme Verlag KG Stuttgart · New York

Lokoregionäre Therapie des HCC

Locoregional Therapy in HCC
T. Helmberger
,
B. Scher
,
B. Kläsner
,
P. Schneider
Further Information

Publication History

Publication Date:
02 February 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das Leberzellkarzinom ist der häufigste Tumor der Leber und gilt als häufigstes Malignom weltweit, mit stetig steigender Inzidenz. Die Behandlungsoptionen werden im Wesentlichen vom Tumorausmaß (Größe, Multifokalität, Leberfunktion, Grunderkrankung der Leber) bestimmt, wobei lokale und systemisch-hepatische Therapien unterschieden werden. Die Tumorresektion und Lebertransplantation gelten als prinzipiell kurative Therapieverfahren, für die sich im klinischen Alltag jedoch lediglich nur ca. 20 % der Patienten qualifizieren. Bei der Mehrzahl der Patienten liegt eine fortgeschrittene Tumorerkrankung ohne oder mit zusätzlicher Lebererkrankung vor. Ist die Tumorlast dabei bez. Tumorgröße und Anzahl noch lokal begrenzt, können perkutane chemoablative, thermoablative und bei mehr multifokaler oder diffuser Tumormanifestation transarterielle chemo- und radioablative Therapieverfahren zum Einsatz kommen. Die Radioablation konkurriert bez. Indikationsstellung mit den transarteriellen, chemoablativen Verfahren (TACE) insbesondere bei Patienten mit fortgeschrittenen Tumoren, wobei sich in ersten Studien Vorteile der Radioembolisation gegenüber TACE hinsichtlich progressionsfreien Überlebens und Gesamtüberlebens zeigen. Diese initialen Ergebnisse müssen jedoch in weiteren Studien untermauert werden.

Abstract

Hepatocellular carcinomas are the most common heaptic tumors and the most common malignancies worldwide with constantly rising incidence. The potential treatment is ruled mainly by the tumor extent (e. g. tumour size, multifocality, hepatic function, underlying concommittend hepatic disease) whereas local from more systemic-hepatic therapies can be differentiated. Resection and transplantation are considered by definition as curative treatments, however, in clinical reality only about 20 % of the patients are eligible for one of this therapies. The majority oft patients will present with an advanced tumor disease with or without an additional hepatic disease. In locally limited tumor burden with respect to tumour size and number percutaneous chemo-ablative, thermo-ablative, and in multifocally or diffuse tumour manifestations transarterial chemo- and radioablative therapies may be administered. Considering indications, radioablation will compete with transarterial, chemoablative trestments (TACE) especially in patients with advanced tumours, whereas in initial studies radioablation presents some advances over TACE regarding progressions-free and overall survival. This promising results have to be confirmed in further studies.

Schlüsselwörter

hepatozelluläres Karzinom - Radioembolisation - selektive interne Radiotherapie (SIRT) - Yttrium-90 - minimal-invasive Therapie

Key words

hepatocellullar carcinoma - radioembolization - selective internal radiotherapy (SIRT) - Yttrium-90 - minimal-invasive therapy
 

  • Literatur

  • 1 Antoch G, Mueller SP, Hamami M et al. Selective internal radiotherapy (SIRT) for hepatocellular carcinoma. Fortschr Röntgenstr 2010; 182: 660-670
    PubMedGoogle Scholar
  • 2 Beland M, Mueller PR, Gervais DA. Thermal ablation in interventional oncology. Semin Roentgenol 2007; 42: 175-190
    CrossrefPubMedGoogle Scholar
  • 3 Benson 3rd AB, Abrams TA, Ben-Josef E et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-391
    PubMedGoogle Scholar
  • 4 Bruix J, Hessheimer AJ, Forner A et al. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006; 25: 3848-3856
    CrossrefPubMedGoogle Scholar
  • 5 Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10 (Suppl. 01) S107-S110
    CrossrefPubMedGoogle Scholar
  • 6 Carr BI, Kondragunta V, Buch SC et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium-90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010; 116: 1305-1314
    CrossrefPubMedGoogle Scholar
  • 7 Clark TW. Chemical ablation of liver cancer. Tech Vasc Interv Radiol 2007; 10: 58-63
    CrossrefPubMedGoogle Scholar
  • 8 Cuomo O, Perrella A, Arenga G. Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?. Transplant Proc 2008; 40: 1906-1909
    CrossrefPubMedGoogle Scholar
  • 9 Dancey JE, Shepherd FA, Paul K et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41: 1673-1681
    PubMedGoogle Scholar
  • 10 Dawson LA, McGinn CJ, Normolle D et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18: 2210-2218
    PubMedGoogle Scholar
  • 11 Geschwind JF, Salem R, Carr BI et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl. 01) S194-S205
    CrossrefPubMedGoogle Scholar
  • 12 Gillams AR. The use of radiofrequency in cancer. Br J Cancer 2005; 92: 1825-1829
    CrossrefPubMedGoogle Scholar
  • 13 Goin JE, Salem R, Carr BI et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005; 16: 195-203
    CrossrefPubMedGoogle Scholar
  • 14 Helmberger T, Dogan S, Straub G et al. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 2007; 75: 104-112
    CrossrefPubMedGoogle Scholar
  • 15 Hilgard P, Hamami M, Fouly AE et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-1749
    CrossrefPubMedGoogle Scholar
  • 16 Huppert PE, Lauchart W, Duda SH et al. Chemoembolization of hepatocellular carcinomas: which factors determine therapeutic response and survival?. Fortschr Röntgenstr 2004; 176: 375-385
    PubMedGoogle Scholar
  • 17 Jakobs TF, Hoffmann RT, Tatsch K et al. Developments and perspectives in radioablative techniques. Radiologe 2007; 47: 1083-1088
    CrossrefPubMedGoogle Scholar
  • 18 Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009; 44 (Suppl. 19) 119-121
    CrossrefPubMedGoogle Scholar
  • 19 Kooby DA, Egnatashvili V, Srinivasan S et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 224-230
    CrossrefPubMedGoogle Scholar
  • 20 Kulik LM, Carr BI, Mulcahy MF et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81
    CrossrefPubMedGoogle Scholar
  • 21 Lau WY, Ho S, Leung TW et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40: 583-592
    CrossrefPubMedGoogle Scholar
  • 22 Lau WY, Ho S, Leung WT et al. What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres?. Hepatogastroenterology 2001; 48: 338-340
    PubMedGoogle Scholar
  • 23 Lau WY, Leung TW, Ho S et al. Diagnostic pharmaco-scintigraphy with hepatic intra-arterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma. Br J Radiol 1994; 67: 136-139
    CrossrefPubMedGoogle Scholar
  • 24 Lee P, Kee S, Busuttil R. Is downstaging prior to liver transplantation important in hepatocellular carcinoma?. Am J Transplant 2009; 9: 1703-1704
    CrossrefPubMedGoogle Scholar
  • 25 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773
    CrossrefPubMedGoogle Scholar
  • 26 Lewandowski RJ, Kulik LM, Riaz A et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9: 1920-1928
    CrossrefPubMedGoogle Scholar
  • 27 Lim L, Gibbs P, Yip D et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 2005; 35: 222-227
    CrossrefPubMedGoogle Scholar
  • 28 Liu MD, Uaje MB, Al-Ghazi MS et al. Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 2004; 70: 947-953
    PubMedGoogle Scholar
  • 29 Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711
    CrossrefPubMedGoogle Scholar
  • 30 Llovet JM, Sala M. Non-surgical therapies of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17: 505-513
    CrossrefPubMedGoogle Scholar
  • 31 Ricke J, Wust P, Stohlmann A et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 2004; 58: 1496-1505
    CrossrefPubMedGoogle Scholar
  • 32 Rossi L, Zoratto F, Papa A et al. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol 2010; 2: 348-359
    CrossrefPubMedGoogle Scholar
  • 33 Salem R, Lewandowski RJ, Atassi B et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-1639
    CrossrefPubMedGoogle Scholar
  • 34 Salem R, Lewandowski RJ, Kulik L et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507 e2
    CrossrefPubMedGoogle Scholar
  • 35 Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64
    CrossrefPubMedGoogle Scholar
  • 36 Sangro B, Bilbao JI, Boan J et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800
    CrossrefPubMedGoogle Scholar
  • 37 Sato K, Lewandowski RJ, Bui JT et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29: 522-529
    CrossrefPubMedGoogle Scholar
  • 38 Schwarz RE, Abou-Alfa GK, Geschwind JF et al. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB 2010; 12: 313-320
    PubMedGoogle Scholar
  • 39 Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology 2004; 13: 73-79
    CrossrefPubMedGoogle Scholar
  • 40 Stefanovic L, Nikolic V, Obradovic M et al. 131-I-lipiodol in therapy of liver carcinoma – methods and case report. Med Pregl 2001; 54: 387-390
    PubMedGoogle Scholar
  • 41 Sutherland LM, Williams JA, Padbury RT et al. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006; 141: 181-190
    CrossrefPubMedGoogle Scholar
  • 42 Tsai AL, Burke CT, Kennedy AS et al. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1377-1384
    CrossrefPubMedGoogle Scholar
  • 43 Van De Wiele C, Defreyne L, Peeters M et al. Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. J Nucl Med Mol Imaging 2009; 53: 317-324
    PubMedGoogle Scholar
  • 44 Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481
    CrossrefPubMedGoogle Scholar
  • 45 Vente MA, Wondergem M, van der Tweel I et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009; 19: 951-959
    Google Scholar
  • 46 Woodall CE, Scoggins CR, Ellis SF et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?. J Am Coll Surg 2009; 208: 375-382
    CrossrefPubMedGoogle Scholar
  • 47 Zhang L, Zhu H, Jin C et al. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol 2009; 19: 437-445
    CrossrefPubMedGoogle Scholar